A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

542

Participants

Timeline

Start Date

December 16, 2011

Primary Completion Date

August 26, 2013

Study Completion Date

August 26, 2013

Conditions
Major Depressive Disorder
Interventions
DRUG

AZD6765 iv

50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.

DRUG

AZD6765 iv

100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.

DRUG

Placebo

0.9 sodium chloride \[normal saline\] solution for injection by iv infusion

Trial Locations (44)

Unknown

Research Site, Chino

Research Site, Lond Beach

Research Site, San Diego

Research Site, Stanford

Research Site, New Heaven

Research Site, Fort Lauderdale

Research Site, Gainsville

Research Site, Lake City

Research Site, Miami

Research Site, Orlando

Research Site, St. Petersburg

Research Site, Atlanta

Research Site, Decatur

Research Site, Hoffman Estates

Research Site, Joliet

Research Site, Skokie

Research Site, Lake Charles

Research Site, Shreveport

Research Site, Baltimore

Research Site, Boston

Research Site, Minneapolis

Research Site, St Louis

Research Site, Willingboro

Research Site, Mount Kisco

Research Site, New York

Research Site, Rochester

Research Site, Winston-Salem

Research Site, Cincinnati

Research Site, Dayton

Research Site, Philadelphia

Research Site, Dallas

Research Site, Houston

Research Site, Bellevue

Research Site, Antofagasta

Research Site, Santiago

Research Site, Bratislava

Research Site, Liptovský Mikuláš

Research Site, Michalovce Stranany

Research Site, Rimavská Sobota

Research Site, Svidník

Research Site, Trnava

Research Site, Cape Town

Research Site, Johannesburg

Research Site, Tygervalley

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY